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Background: Estradiol (E2) is a very potent cytoprotectant against a wide variety of cellular insults in numerous
different cell models, including a Friedreich’s ataxia (FRDA) model. Previously, we demonstrated that estrogen-like
compounds are able to prevent cell death in an FRDA model independent of any known estrogen receptor (ER) by
reducing reactive oxygen species (ROS) and the detrimental downstream effects of ROS buildup including oxidative
damage to proteins and lipids and impaired mitochondrial function.
Results: We have previously demonstrated by western blot that our cell model lacks ERα and expresses only very
low levels of ERβ. Using L-buthionine (S,R)-sulfoximine (BSO) to induce oxidative stress in human FRDA fibroblasts,
we determine the potency and efficacy of the soy-derived ERβ agonist S-equol and its ERα-preferring enantiomer,
R-equol in vitro on cell viability and ROS accumulation. Here we demonstrate that these equol biphenolic
compounds, while significantly less potent and efficacious than E2, provide statistically similar attenuation of ROS
and cytoprotection against a BSO-induced oxidative insult.
Conclusions: These preliminary data demonstrate that estrogen and soy-derived equols could have a beneficial
effect in delaying the onset and decreasing the severity of symptoms in FRDA patients by an antioxidant
mechanism. In addition, these data confirm that the protection seen previously with E2 was indeed unrelated to
ER binding.
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First recognized in 1863 [1], Friedreich’s Ataxia (FRDA)
is the most common hereditary form of ataxia character-
ized by an autosomal recessive GAA trinucleotide repeat
in the FXN gene, resulting in the absence of frataxin
protein [2,3]. The exact function of frataxin is unclear,
however it is necessary for iron metabolism within cells,
Fe-S cluster assembly in proteins, and maintenance of
cellular redox state. Without sufficient levels of frataxin,
reactive oxygen species (ROS) begin to accumulate and
cells are unable to maintain function of Fe-S cluster pro-
teins essential for mitochondrial respiration leading to
mitochondrial dysfunction, insufficient energy produc-
tion and ultimately cell death, beginning in organs with* Correspondence: james.simpkins@unthsc.edu
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distribution, and reproduction in any mediumgreater energy requirements and thus more dependent
on aerobic ATP production, such as the heart, brain and
spinal cord. Symptoms usually begin in the second
decade of life and include ataxia, neural hearing and
ocular abnormalities, scoliosis, diabetes and cardiomyop-
athy, which is the most common cause of premature
death in FRDA patients [for review see Ref 4].
First detected in humans in 1982 [5], equol is a biphe-
nolic isoflavone metabolized from the soy product
daidzein by intestinal flora [6-8] in 14-59% of the human
population [9]. Equol is known to act as an antioxidant
[10,11], decreases circulating estrogens and androgens
[12], inhibits DHT binding to its receptor [13] and
decreases risks of prostate [9,11,14] and breast cancer
[15]. Separation of racemic equol mixtures shows that
S-equol binds with very high affinity to ERβ (Kd ~ 0.73
nM), while its enantiomer, R-equol has a far lower
affinity for ERβ, instead showing a preference for ERα
(Kd ~ 15.4 nM), while E2 has a Kd ~ 0.05-0.1 nM
[16,17]. These enantiomers allow for the discriminationMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Structures of compounds assessed for protection
against BSO toxicity in FRDA fibroblasts.
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due to ERβ activation.
We have previously shown that phenolic estrogens are
able to prevent BSO-induced FRDA skin fibroblast
death, as well as block the formation of ROS [18], pre-
vent lipid peroxidation, protein damage, depletion of
ATP and support the mitochondria and oxidative phos-
phorylation [19]. In the present study, we provide
further evidence that E2 acts by an ERα- and ERβ-
independent mechanism. In addition, we demonstrated a
lack of ERα and a very low level of ERβ in FRDA fibro-
blasts by western blot [19]. Here, we show pharmaco-
logically that ERβ is not contributing to this process, as
R- and S-equol have statistically equivalent efficacies and
potencies, represented here as EC50 values. These data
indicate that it is the phenolic ring present in the com-
pound structure of equol and E2 and not intrinsic recep-
tor binding ability that is responsible for cytoprotective
effects in this FRDA cell model. Although these com-
pounds are substantially less efficacious and potent than
compounds previously used [18], this pharmacologic
model lends support to the non-receptor mediated, non-
genomic antioxidant mechanism of E2.Results
The effects of R- and S-equol on cell viability in BSO-
treated FRDA fibroblasts
To determine the effect of R- and S-equol (Figure 1) on
cell viability, we first assessed their protective potential
compared to 17β-estradiol (E2) at 100nM, a concentration
previously shown to be very protective in this cell model
[18]. At 100nM, both R- and S-equol provided statistically
significant protection compared to the BSO-alone treated
group, however the two groups did not differ significantly
from each other (Figure 2a). E2 also provided significantly
more protection than either of these two compounds
(Figure 2a). A dose–response assessment showed that
R- and S-equol have almost identical cytoprotective pro-
files at all concentrations (Figure 2b), and EC50 evaluation
demonstrated that the two have statistically equivalent
EC50 values (Table 1), indicating that the cytoprotective ef-
fect is not due to stimulation of ERβ.Table 1 EC50 values for R- and S-equol with respect to
cell viability and ROS attenuation
Cell Viability




Compound EC50 (nM) Standard Error (nM)
R-Equol 413.9 34.91
S-Equol 439.1 33.77The effects of R- and S-equol on BSO-induced reactive
oxygen species (ROS) formation
To determine the effects of R- and S-equol on ROS
attenuation, these two compounds were again compared
to E2 (Figure 3a). BSO induced a 2-fold increase of
ROS, which was prevented by 100nM concentrations of
E2, R-equol and S-equol. None of these groups differed
from each other. In addition, a dose response curve for
R- and S-equol shows that there is no significant dif-
ference in the ROS attenuation profiles of these twocompounds at any concentration (Figure 3b), and the
EC50 values do not differ significantly (Table 1).
Discussion
FRDA is the most common of the inherited ataxias world
wide, affecting an estimated 1:50,000 to 1:20,000 people
[2,4]. With the effective loss of functional frataxin
throughout all organ systems, and the resulting ROS pro-
liferation and mitochondrial respiration impairment, cells
in organs most dependent on ATP production begin to
degenerate [4,20]. This results in the loss of cells in the
posterior columns and spinocerebellar tracts of the spinal
cord, resulting in tremor and ataxia, as well as lateral and
kyphoscoliosis, weakness, speech problems, pes cavitus, an
increased incidence of diabetes mellitus and glucose in-
tolerance and cardiac disorders, such as hypertrophic car-
diomyopathy with interstitial fibrosis [4]. Disease onset
Figure 2 A) Effects of 100nM 17β-estradiol, R-equol and
S-equol on cell viability in BSO-treated FRDA fibroblasts. B)
Effects R-equol and S-equol on cell viability in BSO-treated FRDA
fibroblasts. Depicted are mean ± SD for n= 8 per group. * indicated
p<0.05 versus BSO alone-treated cells. † indicated p<0.05 versus BSO
+ R- or S-equol.
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trinucleotide repeats present in the first intron of the FXN
gene, although this alone is not able to account for the full
course of the disease process [21]. There is little difference
between males and females in terms of disease onset, pro-
gress and severity as this is inherited in an autosomal re-
cessive manner and symptoms begin in the first 2 decades
of life, before hormone level changes in puberty [22].
Estrogen and non-feminizing estrogens have been
shown to be potently cytoprotective in many different
cell and animal models of disease states [23,24], includ-
ing a FRDA cell model [18]. Previous observations have
demonstrated that antioxidants, especially mitochond-
rially targeted antioxidants [25,26], including estrogen
receptor agonists and non-feminizing estrogens [18] are
protective against FRDA. These effects have been shown
to be ER independent and are instead based in the anti-
oxidant properties of phenolic estrogens [27,28].
Estrogens exert both genomic and non-genomic effects on
redox status of cells for reviews see [29-34]. Unfortunately,
no studies on the genomic effects of estrogens has been pub-
lished using FRDA cells, but we have reported that these cells
respond to estrogens even in the presence of a pan-estrogen
receptor inhibitors, ICI 182780 [18], have no detectable ERαand low levels of ERβ [19], and exhibit these effects at con-
centrations in excess of the ED50 for 17β-estradiol [18].
Nonetheless, genomic effects of estrogens on antioxidant
enzymes have been reported, which could contribute to
estrogen’s antioxidant effects. For example, tamoxifen is
reported to up-regulated the quinine reductase, NQO1 [29],
and estrogens up-regulate expression of peroxidase-1 and
MnSOD [30]. In contrast, Pajovic and Saicic [31] have
reported that MnSOD, glutathione peroxidase, glutathione-S-
transferase and glutathione reductase are decreased by estra-
diol, whereas catalase is increased. The extent to which the
non-genomic effects of estrogens influence these paradoxical
decreases in antioxidant enzyme expression is not known.
Estrogens are highly lipid soluble (the logarithm of the
octanol/water partition coefficient, log P, is 3.35) and
largely reside in the membrane component of cells [35]
where they are ideally suited to affect oxidation of unsat-
urated bonds in phospholipids. Indeed, estrogens appear
to intercalate into the membrane with their phenolic A
ring situated near the site of lipid peroxidation [36].
We reasoned that estrogens may interrupt lipid peroxi-
dation chain reactions via oxidation in a manner that
could be redox-cycled back to the parent estrogen, using
a plentiful and regenerable source of cellular reducing
potential, such as glutathione or NADPH. We discov-
ered that estrogens were converted via hydroxyl radical
exposure to a quinol product that was, in turn, enzyma-
tically reduced back to the parent estrogen in the pres-
ence of NAD(P)H as a co-factor [27,28]. This estrogen
redox cycle is operative in the central nervous system
[27] where it serves, together with the “classical” antioxi-
dant mechanism for phenolic compounds, as a defense
mechanism against ROS.
Equol is a naturally derived biphenolic (Figure 1) prod-
uct of soy digestion in a substantial percentage of
the American population [5]. It is created by intestinal
flora as a racemic mixture of the R- and S-forms, with
the S-form being very selective for ERβ, the only ER
present in FRDA fibroblasts [19] while the R-form is
only a very weak agonist at this receptor [16,17]. Our
results indicate that, while not as potent or efficacious as
E2 (Figure 2a and 3a) [18], the R- and S-forms of equol
are equally effective in attenuating ROS (Figure 3b,
Table 1) and preventing cell death (Figure 2b, Table 1).
These data indicate that equol, specifically the non-
feminizing R-equol, could potentially be used to prevent
or delay cell death and pathologic symptoms in FRDA
and supports our previous hypothesis that estrogen-like
compounds are acting in a manner unrelated to any
known ER [18,19].
Conclusions
Because the biphenolic compounds R- and S-equol
have statistically equal cytoprotective profiles despite
Figure 3 A.) Effects of 100nM 17β-estradiol, R-equol and
S-equol on ROS accumulation in BSO-treated FRDA fibroblasts.
B.) Effects of 100nM R-equol and S-equol on ROS accumulation in
BSO-treated FRDA fibroblasts. Depicted are mean ± SD for n= 8 per
group. * indicated p<0.05 versus BSO alone-treated cells.
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firm that ERβ is not involved in the protective effects of
E2 seen previously in this FRDA fibroblast model [18,19].
Furthermore, this study demonstrates that estrogen and
soy-derived equols are effective at reducing ROS and im-
proving cell viability in FRDA fibroblasts and shows that
naturally derived soy estrogens could have a beneficial ef-
fect in delaying the onset and decreasing the severity of
symptoms in FRDA patients by an antioxidant mechan-
ism. These data add more weight to the neuroprotective
hypothesis of estrogen and provide evidence that E2 and
other phenol ring-containing estrogens should be consid-
ered as candidate drugs for the treatment and prevention
of the symptoms of FRDA.
Methods
Cell culture
Fibroblasts from a 30 year old Friedreich’s Ataxia
(FRDA) patient (Coriell Institute, Camden NJ, USA)
were maintained in Dulbecco’s Modified Eagle Medium
(DMEM; ThermoScientific, Waltham, MA, USA) with
10% charcoal-stripped fetal bovine serum (CSFBS;
ThermoScientific, Waltham, MA, USA), 1% GlutaMAX
(ThermoScientific, Waltham, MA, USA) and 1%penicillin-streptomycin (Invitrogen, Carlsbad, CA, USA)
at 37°C in 90% humidity and 5% CO2. At the time
of treatment, the FRDA fibroblast media was changed
to phenol red- and sodium pyruvate-free DMEM (Ther-
moScientific, Waltham, MA, USA) and 1% penicillin-
streptomycin. Experiments were conducted using cell
passages 15–19.
Chemicals & reagents
17β-Estradiol (E2) was acquired from Steraloids, Inc.
(Newport, RI, USA). L-buthionine (S,R)-sulfoximine
(BSO) was obtained from Sigma-Aldrich (St Louis, MO,
USA). R- and S- Equol were obtained from the labora-
tory of Dr Robert J Handa at The University of Arizona.
Treatment paradigm
FRDA fibroblasts were removed from culture with 0.25%
Trypsin-EDTA (Invitrogen, Carlsbad, CA, USA) and pla-
ted on 96-well plates at a density of 3000 cells per well in
DMEM with 10% CSFBS, 1% GlutaMAX and 1% penicil-
lin-streptomycin. After 24 hours the media was removed
and replaced with phenol red- and sodium pyruvate-free
DMEM with 1% penicillin-streptomycin. The cells were
then treated for 12 to 48 hours with either dimethyl sulf-
oxide vehicle control (DMSO; Sigma-Aldrich, St Louis,
MO, USA) or 1mM BSO in the presence of E2, R-equol
or S-equol ((3S)-3-(4-Hydroxyphenyl)-7-chromanol). This
duration of exposure was chosen based on our observa-
tion of BSO-induced enhacement of ROS at 12 hours and
cell death at 48 hours [18].
Calcein AM cell viability assay
Cells were plated on a 96-well plate at a density of 5,000
cells per well, then treated with vehicle or 1mM BSO.
After 48 hours of BSO treatment, the media was
removed, and 1 μg/mL Calcein AM (CalBiochem, San
Diego, CA, USA) in phosphate buffer pH 7.2 (PBS;
Fisher Scientific, Pittsburg, PA, USA) was added to each
well and the plate was incubated for 10 minutes at 37°C.
Cell viability was determined with a Tecan Infinite M200
(Tecan Systems, Inc., San Jose, CA) plate reader with an
excitation of 490nm and emission of 520nm at 48 hours.
Reactive oxygen species assay
After 12 hours of treatment the media was removed
from each well of the 96-well plate, and 100μL of a 1μM
2’,7’-Dichlorodihydrofluorescein diacetate (DCFDA; Ana-
Spec Inc., Fremont, CA, USA) in PBS was added to each
well. The plates were returned to a 37°C incubator for
20 minutes, then each well was washed three times
with PBS and the resulting reaction was read on a Tecan
Infinite M200 plate reader with an absorbance of
495 nm and an emission of 529 nm.
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All data are displayed as mean ± 1 standard deviation.
These data were analyzed using the ANOVA against an
alpha level of 0.05. All bar graphs were made using
GraphPad Prism 5 and EC50 calculations were made with
GraphPad Prism 5. For all groups, n=8 wells and experi-
ments were repeated three times to ensure consistency.
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